antibodies - online.com





Datasheet for ABIN5668207

Recombinant anti-RSV (Felvizumab Biosimilar) antibody



1 4 1	9W

Quantity:	200 μg
Target:	RSV (Felvizumab Biosimilar)
Reactivity:	Respiratory Syncytial Virus (RSV)
Host:	Rabbit
Antibody Type:	Recombinant Antibody
Clonality:	Monoclonal
Conjugate:	This RSV (Felvizumab Biosimilar) antibody is un-conjugated
Application:	ELISA, Functional Studies (Func)
Product Details	
Immunogen:	This antibody was prepared by the humanization of an F protein-specific murine MAb, RSV19.
	More specifically, molecular techniques were used to insert the complementarity determining
	More specifically, molecular techniques were used to insert the complementarity determining regions from murine RSV19 into a human IgG1 heavy and k light chain-variable domain
Clone:	regions from murine RSV19 into a human IgG1 heavy and k light chain-variable domain
Clone:	regions from murine RSV19 into a human IgG1 heavy and k light chain-variable domain framework.
	regions from murine RSV19 into a human IgG1 heavy and k light chain-variable domain framework. RSHZ19
Isotype:	regions from murine RSV19 into a human IgG1 heavy and k light chain-variable domain framework. RSHZ19 IgG kappa
Isotype: Specificity:	regions from murine RSV19 into a human IgG1 heavy and k light chain-variable domain framework. RSHZ19 IgG kappa This antibody is specific for the conserved fusion (F) protein of RSV.

Product Details	
Purity:	> 98 % as determined by SDS-PAGE
Endotoxin Level:	Endotoxin is < 1.0 EU/mg as determined by the LAL method
Target Details	
Target:	RSV (Felvizumab Biosimilar)
Abstract:	RSV (Felvizumab Biosimilar) Products
Target Type:	Biosimilar
Background:	SB 209763, respiratory syncytial virus
Application Details	
Application Notes:	Though shown to be safe and well-tolerated (Everitt, 1996) and protective against RSV infection in BALB/c mice and cotton rats (Wyde, 1995), this antibody did not demonstrate efficacy in a Phase 3 study (Reichert, 2008). In in vitro studies, palivizumab, another humanized Mab specific for the F protein of RSV, was 4 to 5-fold more potent than felvizumab in neutralising RSV (Scott, 1999).
Comment:	This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques.
Restrictions:	For Research Use only
Handling	
Buffer:	PBS with 0.02 % Proclin 300.
Preservative:	ProClin
Precaution of Use:	This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Storage:

Storage Comment:

4 °C,-20 °C